KLK3 and pachyonychia congenita: For men with newly diagnosed PC, critical factors that guide initial treatment selection include tumor–node–metastasis (TNM) stage, International Society of Urological Pathology (ISUP) grade group, serum PSA, D’Amico risk classification, and age with life expectancy as well as individual preferences [4].